Physician profile
Robert D Pfeffer
NPI 1679563639
$1,374.31
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $15.98 · 2021: $246 · 2022: $414 · 2023: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $282.12 | 2019-2023 | Opdivo |
| Astellas Pharma US INC | $148.94 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $137.65 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $100.72 | 2019-2023 | Imbruvica |
| Boston Scientific Corporation | $91.81 | 2022 | |
| Genzyme Corporation | $77.17 | 2019 | |
| Recordati_rare_diseases_inc. | $65.94 | 2023 | Sylvant |
| Incyte Corporation | $59.03 | 2019 | |
| Janssen Biotech, INC. | $57.00 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $40.46 | 2021-2022 | |
| Genentech USA, INC. | $38.21 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.50 | 2022-2023 | Keytruda, Welireg, Lynparza |
| Elekta, INC. | $27.73 | 2022 | |
| Siemens Medical Solutions USA, INC. | $18.64 | 2022 | |
| Myovant Sciences INC. | $17.04 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $16.45 | 2023 | |
| Adaptive Biotechnologies Corporation | $16.00 | 2022 | |
| Aveo Pharmaceuticals, INC. | $15.98 | 2022 | |
| Foundation Medicine, INC. | $14.99 | 2022 | |
| Blueprint Medicines Corporation | $13.99 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.45 | 2021 | |
| Amgen INC. | $13.37 | 2019 | |
| Morphosys, US INC. | $13.35 | 2023 | Monjuvi |
| Celgene Corporation | $13.33 | 2019 | |
| Spectrum Pharmaceuticals INC. | $12.98 | 2019 | |
| Abbvie INC. | $12.59 | 2019 | |
| Pfizer INC. | $11.99 | 2019 | |
| Novocure INC. | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pfeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.